PubMed:26684240 / 973-1167 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"11005","span":{"begin":6,"end":13},"obj":"DiseaseOrPhenotypicFeature"},{"id":"11006","span":{"begin":14,"end":22},"obj":"OrganismTaxon"},{"id":"11007","span":{"begin":28,"end":32},"obj":"GeneOrGeneProduct"},{"id":"11008","span":{"begin":89,"end":115},"obj":"DiseaseOrPhenotypicFeature"},{"id":"11009","span":{"begin":116,"end":123},"obj":"OrganismTaxon"},{"id":"11010","span":{"begin":129,"end":133},"obj":"GeneOrGeneProduct"},{"id":"11011","span":{"begin":134,"end":139},"obj":"SequenceVariant"},{"id":"11012","span":{"begin":174,"end":183},"obj":"ChemicalEntity"}],"attributes":[{"id":"A35","pred":"db_id","subj":"11005","obj":"MESH:C535650"},{"id":"A36","pred":"db_id","subj":"11006","obj":"NCBITaxon:9606"},{"id":"A37","pred":"db_id","subj":"11007","obj":"NCBIGene:7157"},{"id":"A38","pred":"db_id","subj":"11008","obj":"MESH:D007414"},{"id":"A39","pred":"db_id","subj":"11009","obj":"NCBITaxon:9606"},{"id":"A40","pred":"db_id","subj":"11010","obj":"NCBIGene:673"},{"id":"A41","pred":"db_id","subj":"11011","obj":"DBSNP:rs113488022"},{"id":"A42","pred":"db_id","subj":"11012","obj":"MESH:C516667"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment."}

{"project":"LitCoin-sentences","denotations":[{"id":"T7","span":{"begin":0,"end":194},"obj":"Sentence"}],"text":"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment."}

{"project":"LitCoin-SeqVar","denotations":[{"id":"T2","span":{"begin":134,"end":139},"obj":"SequenceVariant"}],"text":"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T23","span":{"begin":10,"end":13},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":28,"end":32},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":83,"end":88},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":89,"end":99},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":112,"end":115},"obj":"GeneOrGeneProduct"},{"id":"T28","span":{"begin":129,"end":133},"obj":"GeneOrGeneProduct"}],"text":"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T46","span":{"begin":10,"end":13},"obj":"GeneOrGeneProduct"},{"id":"T47","span":{"begin":28,"end":32},"obj":"GeneOrGeneProduct"},{"id":"T48","span":{"begin":33,"end":42},"obj":"GeneOrGeneProduct"},{"id":"T49","span":{"begin":83,"end":88},"obj":"GeneOrGeneProduct"},{"id":"T50","span":{"begin":89,"end":99},"obj":"GeneOrGeneProduct"},{"id":"T51","span":{"begin":112,"end":115},"obj":"GeneOrGeneProduct"},{"id":"T52","span":{"begin":129,"end":133},"obj":"GeneOrGeneProduct"},{"id":"T53","span":{"begin":140,"end":148},"obj":"GeneOrGeneProduct"}],"text":"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment."}

{"project":"LitCoin-GeneOrGeneProduct-v3","denotations":[{"id":"T22","span":{"begin":10,"end":13},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":28,"end":32},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":112,"end":115},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":129,"end":133},"obj":"GeneOrGeneProduct"}],"text":"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T8","span":{"begin":6,"end":13},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A8","pred":"mondo_id","subj":"T8","obj":"0024503"}],"text":"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T8","span":{"begin":6,"end":13},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":89,"end":115},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A8","pred":"ID:","subj":"T8","obj":"DISEASE"},{"id":"A9","pred":"ID:","subj":"T9","obj":"DISEASE"}],"text":"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T8","span":{"begin":6,"end":13},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T9","span":{"begin":89,"end":115},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A8","pred":"#label","subj":"T8","obj":"DISEASE"},{"id":"A9","pred":"#label","subj":"T9","obj":"DISEASE"}],"text":"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T3","span":{"begin":174,"end":183},"obj":"ChemicalEntity"}],"attributes":[{"id":"A3","pred":"ID:","subj":"T3","obj":"C516667"},{"id":"A4","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_71219"}],"text":"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T2","span":{"begin":14,"end":22},"obj":"OrganismTaxon"},{"id":"T3","span":{"begin":116,"end":123},"obj":"OrganismTaxon"}],"text":"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T3","span":{"begin":174,"end":183},"obj":"ChemicalEntity"},{"id":"T25","span":{"begin":129,"end":133},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":112,"end":115},"obj":"GeneOrGeneProduct"},{"id":"T23","span":{"begin":28,"end":32},"obj":"GeneOrGeneProduct"},{"id":"T22","span":{"begin":10,"end":13},"obj":"GeneOrGeneProduct"},{"id":"T48673","span":{"begin":89,"end":115},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T20286","span":{"begin":6,"end":13},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T57822","span":{"begin":116,"end":123},"obj":"OrganismTaxon"},{"id":"T87458","span":{"begin":14,"end":22},"obj":"OrganismTaxon"},{"id":"T55890","span":{"begin":134,"end":139},"obj":"SequenceVariant"}],"attributes":[{"id":"A4","pred":"ID:","subj":"T3","obj":"http://purl.obolibrary.org/obo/CHEBI_71219"},{"id":"A3","pred":"ID:","subj":"T3","obj":"C516667"},{"id":"A9","pred":"#label","subj":"T48673","obj":"DISEASE"},{"id":"A8","pred":"#label","subj":"T20286","obj":"DISEASE"}],"text":"Three GEP-NET patients with TP53 mutations demonstrated a durable response and one small intestinal grade (G) 1 NET patient with BRAF V600E mutation showed progression after pazopanib treatment."}